Clinical trial
Sorafenib and Anastrozole in Treating Postmenopausal Women With Metastatic…
NCT00217399 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00217399 |
|---|---|
| Title | Sorafenib and Anastrozole in Treating Postmenopausal Women With Metastatic Breast Cancer |
| Official title | A Phase I/II Trial of BAY 43-9006 (Sorafenib) in Combination With Anastrozole in Patients With Metastatic Breast Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Recurrent Breast Cancer, Stage IV Breast Cancer |
| Intervention type | Drug |
| Interventions | sorafenib tosylate, anastrozole |
| Enrollment | 35 |
| Start date | Jun 1, 2005 |
| Primary completion | Jul 1, 2009 |
| Completion | Jan 1, 2013 |
| First posted | Sep 22, 2005 |
| Last update posted | May 28, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: